Redwood City, California 94065


Purpose:

This study is being conducted to document the safety, clinical effectiveness and cost-effectiveness of high-frequency SCS at 10 kHz (HF10™ Therapy) delivered through the Senza system in subjects with chronic refractory back pain (with or without leg pain) who are not considered candidates for spine surgery. This study is a multi-center, prospective, randomized study to compare the two treatment groups.


Criteria:

Key Inclusion Criteria: 1. Have been diagnosed with chronic, refractory axial low back pain with a neuropathic component and are not eligible for spine surgery 2. Have not had any surgery for back or leg pain, or any surgery resulting in back or leg pain 3. Qualifying pain score 4. Be on stable pain medications, as determined by the Investigator 5. Be willing and capable of giving informed consent 6. Be willing and able to comply with study-related requirements, procedures, and visits 7. Be capable of subjective evaluation, able to read and understand written questionnaires in the local language and are able to read, understand and sign the written inform consent Key Exclusion Criteria: 1. Have a diagnosed back condition with inflammatory causes of back pain, serious spinal pathology and/or neurological disorders 2. Have a medical condition or pain in other area(s), not intended to be treated in this study 3. Any diagnosis or known condition that can impact reporting of study outcomes as determined by the Investigator 4. Be benefitting within 30 days prior to enrollment from an interventional procedure to treat back and/or leg pain 5. Have any addictions as determined by the Investigator 6. Have an existing drug pump and/or SCS system or another active implantable device such as a pacemaker 7. Have prior experience with neuromodulation devices 8. Other general exclusions applicable for SCS devices 9. Be involved in an injury claim under current litigation 10. Have a pending or approved worker's compensation claim


NCT ID:

NCT03680846


Primary Contact:

Study Director
David Caraway, MD
Nevro Corp

Brad Gliner
Phone: 650-433-3228
Email: gliner@nevro.com


Backup Contact:

N/A


Location Contact:

Redwood City, California 94065
United States

Brad Gliner

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.